147 employees
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
1987
$60M
from 3 investors over 3 rounds
pSivida raised $16M on January 3, 2021
Investors: Ocumension
pSivida raised $60M on February 13, 2019
Investors: CRG LP
pSivida raised $7M on March 13, 2014
Investors: RA Capital Management, L.P.